Pertuzumab, emtansine, lapatinib, and neratinib are among the approved HER2 targeting breast cancer therapies to have a less detrimental effect on cardiac tissue than trastuzumab and to be more effective and safer in people with cardiac risk factors [56]. This evidence concerns the gene ERBB2 and breast cancer.